New Age Alpha Advisors LLC Makes New Investment in Option Care Health, Inc. (NASDAQ:OPCH)

New Age Alpha Advisors LLC bought a new stake in Option Care Health, Inc. (NASDAQ:OPCH) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 6,389 shares of the company’s stock, valued at approximately $148,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Norges Bank acquired a new stake in Option Care Health in the fourth quarter worth about $60,219,000. Loomis Sayles & Co. L P grew its position in shares of Option Care Health by 2.8% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,050,549 shares of the company’s stock worth $24,372,000 after buying an additional 28,790 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Option Care Health by 29.6% during the fourth quarter. JPMorgan Chase & Co. now owns 1,511,403 shares of the company’s stock worth $35,065,000 after buying an additional 344,875 shares during the last quarter. Murphy & Mullick Capital Management Corp bought a new stake in shares of Option Care Health during the fourth quarter worth approximately $26,000. Finally, Florida Financial Advisors LLC acquired a new position in Option Care Health in the fourth quarter valued at approximately $211,000. Institutional investors own 98.05% of the company’s stock.

Option Care Health Stock Performance

Shares of OPCH stock opened at $34.79 on Thursday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.32 and a current ratio of 1.73. Option Care Health, Inc. has a 52 week low of $21.39 and a 52 week high of $35.53. The company’s 50 day moving average price is $32.80 and its two-hundred day moving average price is $28.47. The company has a market capitalization of $5.71 billion, a P/E ratio of 29.24, a price-to-earnings-growth ratio of 2.30 and a beta of 1.33.

Analysts Set New Price Targets

Several analysts have commented on the stock. Jefferies Financial Group upgraded shares of Option Care Health from a “hold” rating to a “buy” rating and upped their target price for the company from $26.00 to $35.00 in a research report on Thursday, January 23rd. UBS Group started coverage on Option Care Health in a research note on Thursday, December 5th. They issued a “neutral” rating and a $26.00 target price on the stock. Barrington Research raised their target price on Option Care Health from $33.00 to $38.00 and gave the stock an “outperform” rating in a report on Thursday, February 27th. JMP Securities reaffirmed a “market outperform” rating and issued a $30.00 price target (down from $31.00) on shares of Option Care Health in a research note on Friday, January 10th. Finally, Bank of America raised shares of Option Care Health from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $26.00 to $33.00 in a research note on Monday, January 13th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $33.00.

Insider Buying and Selling

In other Option Care Health news, insider Michael Bavaro sold 30,996 shares of the stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $33.26, for a total transaction of $1,030,926.96. Following the completion of the transaction, the insider now owns 44,974 shares in the company, valued at approximately $1,495,835.24. This represents a 40.80 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.64% of the stock is currently owned by company insiders.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.